MX2024002886A - Metodos para tratar enfermedades neurodegenerativas. - Google Patents

Metodos para tratar enfermedades neurodegenerativas.

Info

Publication number
MX2024002886A
MX2024002886A MX2024002886A MX2024002886A MX2024002886A MX 2024002886 A MX2024002886 A MX 2024002886A MX 2024002886 A MX2024002886 A MX 2024002886A MX 2024002886 A MX2024002886 A MX 2024002886A MX 2024002886 A MX2024002886 A MX 2024002886A
Authority
MX
Mexico
Prior art keywords
methods
neurodegenerative diseases
treating neurodegenerative
forms
mapt
Prior art date
Application number
MX2024002886A
Other languages
English (en)
Spanish (es)
Inventor
Xiaoyan Zhang
Scott J Barraza
Jeffrey K Trimmer
Yong Yu
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2024002886A publication Critical patent/MX2024002886A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2024002886A 2021-09-07 2022-09-06 Metodos para tratar enfermedades neurodegenerativas. MX2024002886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163260942P 2021-09-07 2021-09-07
PCT/US2022/075966 WO2023039368A1 (en) 2021-09-07 2022-09-06 Methods for treating neurogenerative diseases

Publications (1)

Publication Number Publication Date
MX2024002886A true MX2024002886A (es) 2024-05-24

Family

ID=85506882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002886A MX2024002886A (es) 2021-09-07 2022-09-06 Metodos para tratar enfermedades neurodegenerativas.

Country Status (7)

Country Link
US (1) US20240382491A1 (https=)
EP (1) EP4398986A4 (https=)
JP (1) JP2024533263A (https=)
CN (1) CN118251225A (https=)
CA (1) CA3230996A1 (https=)
MX (1) MX2024002886A (https=)
WO (1) WO2023039368A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012656A2 (en) * 2010-07-21 2012-01-26 University Of South Florida Materials and methods for treating neurodegenerative diseases
EP2867236B1 (en) * 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
CA2973949C (en) * 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Also Published As

Publication number Publication date
EP4398986A1 (en) 2024-07-17
WO2023039368A1 (en) 2023-03-16
CA3230996A1 (en) 2023-03-16
CN118251225A (zh) 2024-06-25
JP2024533263A (ja) 2024-09-12
US20240382491A1 (en) 2024-11-21
EP4398986A4 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
MX2024005335A (es) Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos.
NI201900060A (es) Inhibidores de moléculas pequeñas de la familia de quinasa jak
PE20191499A1 (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
MX385576B (es) Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2
UY37781A (es) Proceso para la preparación de pirazolo[1,5-a] pirimidinas y sales de las mismas
UY36176A (es) Formas cristalinas de (2r, 5s, 13ar)-8-hidroxi-7,9- dioxo- n-(2,4,6 - trifluorobencil)-2,3,4,5,7,9,13,13a -octahidro -2,5- metanopirido[1?,2?,4,5]pirazino[2,1-b][1,3]oxazapina- 10-carboxamida
EA201791274A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
CO2018005163A2 (es) Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo
MX2016015874A (es) Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
MX2024002886A (es) Metodos para tratar enfermedades neurodegenerativas.
MX2011007102A (es) Proceso para preparar inhibidores de proteinas janus cinasas (jak) y compuestos intermediarios relacionados.
MX2018004332A (es) Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas.
MX2020013896A (es) Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
CL2020003227A1 (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak.
EA201691930A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-α][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1
CY1125323T1 (el) ΚΥΚΛΙΚΑ ΠΑΡΑΓΩΓΑ ΑΙΘΕΡΑ ΤΟΥ ΠΥΡΑΖOΛO[1,5- a]ΠΥΡΙΜΙΔΙΝO-3-ΚΑΡΒOΞΥΑΜΙΔΙOΥ
MX2019005123A (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
MX2024002887A (es) Metodos para tratar enfermedades neurodegenerativas.
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
MX2019005115A (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
CL2018002344A1 (es) Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina
CO2021009660A2 (es) Proceso para preparar rogaratinib y sus estados sólidos
CL2021001447A1 (es) Formas cristalinas a, b, d, i de 1–(6–((6–((1r)–1–hidroxietil)–8–isopropilamino)pirido[3,4–d]pirimidin–2–il)amino)–3–piridil)piperazin–2–ona; composición farmacéutica que las comprende; y su uso para tratar artritis reumatoide, arteriosclerosis, entre otras enfermedades (divisional solicitud 201901420).